2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
(2013)
Journal Article
MD, P. A. G., PhD, P. R. D. G., MD, P. M. J. P., MD, E. D. A., MSci, M. P., MD, P. T. M. S., …MD †, P. J. B. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/S0140-6736%2813%2961094-6
Professor Adrian Brunt's Outputs (2)
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (2013)
Journal Article
RD Johnston, S., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., …investigators, S. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, 14(10), 989-998. https://doi.org/10.1016/S1470-2045%2813%2970322-X